deltatrials
Suspended PHASE3 INTERVENTIONAL 2-arm NCT00865488

Evaluation of Adhexil Safety and Efficacy in Prevention and/or Reduction of Adhesions in Gynecological Surgery

A Prospective, Controlled, Randomized, Multi-Center, Pivotal Study Evaluating the Safety and Efficacy of AdhexilTM in Prevention And/Or Reduction of Adhesions in Gynecology Surgery

Sponsor: OMRIX Biopharmaceuticals

Conditions Adhesions Endometriosis Ovarian Cysts
Interventions ADHEXIL
Updated 7 times since 2017 Last updated: Dec 20, 2009 Started: May 31, 2009 Primary completion: Feb 28, 2010 Completion: Apr 30, 2010
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Suspended

This trial was suspended. No reason was provided.

This PHASE3 trial investigates Adhesions and Endometriosis and is currently suspended. OMRIX Biopharmaceuticals leads this study, which shows 7 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotSuspended~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotSuspended~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotSuspended~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotSuspended~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotSuspended~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotSuspended~Sep 2025 – present · 9 months · monthly snapshotSuspended

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Suspended PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Suspended PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Suspended PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Suspended PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Suspended PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Suspended PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Suspended PHASE3

    First recorded

May 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • OMRIX Biopharmaceuticals
Data source: OMRIX Biopharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations